Paysign, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Paysign reported Q2 2026 revenue of $28.25M (up 48.1% YoY), with Pharma revenue surging 88.9% to $14.65M (51 net programs added) and Plasma revenue rising 21.4% to $13.04M despite 46 net center closures. Net income reached $6.76M ($0.11 diluted EPS) vs. $1.39M ($0.02 EPS) in Q2 2025; Adjusted EBITDA doubled to $9.61M. Company raised FY2026 guidance to $114.0M–$117.0M revenue (vs. prior range implied lower) and $35.0M–$38.0M Adjusted EBITDA, with gross margin expanding to 63.3% and operating margin at 24.8% (21.3% excluding a $990K non-cash fair-value gain on contingent consideration from Gamma acquisition).
Why this rating
Strong growth (48% revenue, 387% net income), significant margin expansion, and raised guidance are materially positive; 10.3% of market cap in annualized revenue and 16% in Adjusted EBITDA signals real operating leverage—meaningful for a $276M company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.